Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Omnicell, Inc. - Common Stock (NQ:OMCL)

35.16 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Omnicell, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Three Earnings Reports Put the Automation Rally to the Test ↗
Via Chartmill
News headline image
3 Small-Cap Stocks We Approach with Caution
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and... 
Via StockStory
News headline image
Omnicell President Sells 6,753 Shares ↗
Nnamdi Njoku's disposal reduced his direct holdings by 4%, with over half tied to tax withholding from RSU vesting. He retains ~161,223 shares worth $5.81 million. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Omnicell Q2 Earnings Call Highlights ↗
Omnicell (NASDAQ:OMCL) reported second-quarter 2026 revenue at the high end of its prior outlook and profitability above expectations, while widening its full-year product bookings range to reflect... 
Via MarketBeat
Topics Earnings World Trade
Omnicell (NASDAQ:OMCL) Q2 Earnings Beat Overshadowed by Disappointing Guidance ↗
Via Chartmill
Topics Earnings
Nvidia, Teradyne, and Omnicell Earnings Set to Test Robotics Sector’s Divergent Momentum ↗
Via Chartmill
Beyond the AI Titans: Niche Automation Plays Show Strong Momentum and Earnings Acceleration ↗
Via Chartmill
Topics Artificial Intelligence
News headline image
Omnicell (OMCL) Stock Trades Down, Here Is Why
What Happened? Shares of healthcare tech company Omnicell (NASDAQ:OMCL) fell 9.9% in the afternoon session after the company issued weak guidance for the upc... 
Via StockStory
Topics Artificial Intelligence
News headline image
Omnicell’s (NASDAQ:OMCL) Q2 CY2026: Beats On Revenue But Stock Drops On Weak Guidance
Healthcare tech company Omnicell (NASDAQ:OMCL) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 7.4% year on year to $312.2 million. On th... 
Via StockStory
News headline image
Omnicell (OMCL) Reports Q2: Everything You Need To Know Ahead Of Earnings
Healthcare tech company Omnicell (NASDAQ:OMCL) will be announcing earnings results this Thursday morning. Here’s what investors should know. Omnicell beat an... 
Via StockStory
News headline image
2 Cash-Heavy Stocks to Target This Week and 1 We Turn Down
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg... 
Via StockStory
News headline image
1 Healthcare Stock to Target This Week and 2 We Brush Off
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as... 
Via StockStory
News headline image
Unpacking Q1 Earnings: Tandem Diabetes (NASDAQ:TNDM) In The Context Of Other Healthcare Technology Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how healthcare technology ... 
Via StockStory
News headline image
3 Small-Cap Stocks We’re Skeptical Of
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and... 
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
Q1 Earnings Highlights: GoodRx (NASDAQ:GDRX) Vs The Rest Of The Healthcare Technology Stocks
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare technology industry, includ... 
Via StockStory
News headline image
1 Profitable Stock with Exciting Potential and 2 That Underwhelm
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does... 
Via StockStory
News headline image
3 Russell 2000 Stocks That Fall Short
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,... 
Via StockStory
News headline image
Q1 Rundown: Privia Health (NASDAQ:PRVA) Vs Other Healthcare Technology for Providers Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a... 
Via StockStory
News headline image
3 Healthcare Stocks We Think Twice About
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory de... 
Via StockStory
News headline image
A Look Back at Healthcare Technology for Providers Stocks’ Q1 Earnings: Astrana Health (NASDAQ:ASTH) Vs The Rest Of The Pack
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare technology for providers in... 
Via StockStory
News headline image
Healthcare Technology for Providers Stocks Q1 Earnings: Omnicell (NASDAQ:OMCL) Best of the Bunch
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the healthcare technology for providers in... 
Via StockStory
News headline image
Spotting Winners: Hims & Hers Health (NYSE:HIMS) And Healthcare Technology Stocks In Q1
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including Hims & Hers Health (NYSE:HIMS) and its peer... 
Via StockStory
News headline image
3 Reasons to Avoid OMCL and 1 Stock to Buy Instead
Omnicell’s 23% return over the past six months has outpaced the S&P 500 by 13%, and its stock price has climbed to $43.73 per share. This was partly due to i... 
Via StockStory
Topics Stocks
News headline image
3 Stocks Under $50 with Warning Signs
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha... 
Via StockStory
News headline image
3 Cash-Producing Stocks We Keep Off Our Radar
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not... 
Via StockStory
News headline image
The 5 Most Interesting Analyst Questions From Omnicell’s Q1 Earnings Call
Omnicell’s first quarter was marked by strong execution and operational improvements, leading to results that exceeded Wall Street’s expectations. Management... 
Via StockStory
Topics Earnings
News headline image
1 Small-Cap Stock to Keep an Eye On and 2 We Ignore
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th... 
Via StockStory
News headline image
Investment Advisor Sells $6.6 Million Worth of Medical Solutions Stock, According to Recent SEC Filing ↗
Omnicell provides automation and software solutions to streamline medication management for healthcare systems and pharmacies. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
OMCL Q1 Deep Dive: Platform Expansion and Cost Controls Drive Margin Turnaround
Healthcare tech company Omnicell (NASDAQ:OMCL) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with sales up 14.9% year on year to $30... 
Via StockStory
Topics World Trade
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.